5.35
+0.09(+1.71%)
Currency In USD
Address
400 Fifth Avenue
Waltham, MA 02451
United States of America
Phone
510 745 1700
Website
Sector
Healthcare
Industry
Biotechnology
Employees
395
First IPO Date
June 19, 2014
| Name | Title | Pay | Year Born |
| Mr. Michael G. Raab | President, Chief Executive Officer & Director | 1.03M | 1965 |
| Mr. Robert C. Blanks | Chief Regulatory Affairs & Quality Assurance Officer | 590,800 | 1960 |
| Mr. Justin A. Renz CPA, MBA | Chief Financial & Operations Officer | 623,700 | 1972 |
| Mr. David P. Rosenbaum | Chief Development Officer | 645,400 | 1961 |
| Dr. Laura A. Williams M.D., M.P.H. | Chief Medical Officer | 664,810 | 1964 |
| Ms. Elizabeth A. Grammer Esq. | Chief Legal & Administrative Officer and Secretary | 668,250 | 1964 |
| Mr. Eric Duane Foster | Chief Commercial Officer | 0 | N/A |
| Mr. Joseph Reilly | Senior Vice President of Finance & Principal Accounting Officer | 0 | 1974 |
| Mr. Mike Kelliher | Executive Vice President of Corporate Development & Strategy | 0 | 1977 |
| Ms. Caitlin Lowie | Vice President of Corporate Communications & Investor Relations | 0 | N/A |
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.